Agreement with statements regarding impact of NTM-LD on morbidity and mortality
| Countries | Strongly agree | Agree | Unsure | Disagree | Strongly disagree |
| ‘NTM-LD significantly increases morbidity and leads to more frequent hospitalisations’* | |||||
| UK | 12 | 73 | 12 | 3 | 0 |
| Germany | 25 | 58 | 15 | 2 | 0 |
| Italy | 13 | 67 | 10 | 10 | 0 |
| France | 22 | 70 | 8 | 0 | 0 |
| The Netherlands | 13 | 65 | 20 | 3 | 0 |
| Mean percentage | 17 | 67 | 13 | 4 | 0 |
| ‘NTM-LD has no significant impact on mortality risk, as mortality is determined by the underlying condition’ | |||||
| UK | 3 | 10 | 23 | 55 | 8 |
| Germany | 0 | 7 | 18 | 53 | 22 |
| Italy | 0 | 13 | 32 | 43 | 12 |
| France | 2 | 20 | 28 | 32 | 18 |
| The Netherlands | 3 | 10 | 25 | 53 | 10 |
| Mean percentage | 1 | 12 | 25 | 47 | 14 |
The percentage of physicians choosing an answer is shown. n=280.
*Agreement with this statement weakly correlated with perceived risk of NTM in patients with bronchiectasis (Spearman’s r 0.185, p<0.01) and number of patients with NTM managed (Spearman’s r 0.174, p<0.01).
NTM-LD, non-tuberculous mycobacterial lung disease.